Disease activity free status on Alemtuzumab vs. IFNbeta-1a (CAREMS 1 Study)http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=giovannonipresentation0288oralsession17ens2012final-120611085055-phpapp02&stripped_title=disease-activity-free-status-on-alemtuzumab-vs-ifnbeta1a-carems-1-study&userName=gavingiovannoni
View more presentations from gavingiovannoni.
“My slides from my presentation at the European Neurological Society Meeting in Prague. The analysis shows that alemtuzumab is more effective than interferon-beta-1a (Rebif) in rendering someone with active MS free of disease activity using clinical and MRI markers of disease activity.”
CoI: Multiple
CoI: Multiple
I see that 74% of alemtuzumab treated patients are CDA free at 2 years, but only 51% are MRI activity free. Would you expect this MRI activity to result in CDA at some later stage, or do you think the MRI activity would reduce of its own volition, or would this be a reason to have a 3rd alemtuzumab dose after a few years? It would be interesting to see these comparisons done after 5 years. Have you heard anymore about Alistair Coles data on progression and alemtuzumab?
Re: "Do you think the MRI activity would reduce of its own volition, or would this be a reason to have a 3rd alemtuzumab dose after a few years?"Alemtuzumab takes 8-12 weeks to start working therefore any MRI activity in the first 3 months of the study will be counted as activity. Therefore I would expect MRI activity to decrease with time.You have to realise that MS is line an iceberg; relapse above the water with MRI activity below the water. There is little doubt in my mind that sub-clinical MRI activity is associate with later progression. Our aim is therefore to suppress all evidence of disease activity. Yes, subclinical MRI activity after the 2 course of infusions will be used as an indication for a third course.